Default company panoramic image
Af79993b 2ab8 4816 825a f4800a2f6cb2

TDP Biotherapeutics, Inc.

TDP is developing an anticancer drug that inhibits cancer and leaves normal cells unharmed. Product is ready for Pharm/Tox then Orphan IND.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Gaithersburg, MD, USA
  • Currency USD
  • Founded October 2010
  • Employees 1

Company Summary

TDP Biotherapeutics holds the exclusive license to a highly targeted anticancer drug that interferes with a protein manifested by cancer cells but not by normal cells. The synthesis, formulation, manufacturing methods, in vivo proof of concept, BA/PK are all complete. The company seeks $1.5 million to bring the product through IND enabling Pharm/Tox before initiating a first in human study in an orphan indication.


  • Default avatar
    Lisa Beth Ferstenberg, M.D.
    President, CEO

    LBF is a serial entrepreneur with 30 year history of cancer/immunology drug development and successful exit. Using resources for high level contractors, she runs TDP as virtual, focusing all investment on moving toward IND. Her depth of experience in every phase of drug development makes this feasible, and her business experience makes this cost effective. LBF teaches entrepreneurship at Hopkins/UMD and is known for creative business solutions


  • Default avatar
    Polsinelli Shughart, PC
    Default avatar

Previous Investors

  • Default avatar
    Dani's Foundation
    Default avatar
    LB Ferstenberg, M.D.